RxDoctor Payments Data

Bonita Clayton

Family · Washington, PANPI 1023172590

Payments from drug & device makers

$1,255in general payments, 2019–2025

Across 59 payments — averaging $21.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$959
  • AstraZeneca$125
  • Lilly USA, LLC$48
  • Appliedvr Inc$38
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$23
  • Novo Nordisk$17
  • plus $44 from 3 others

What the payments were for

  • Food & beverage$1,255100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,255 in reported general payments places this provider in the 75th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$7,525
Medicare patients
46
Services billed
145

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide15$14,071
JanumetSitagliptin Phos/Metformin Hcl13$7,693
Lagevrio (Eua)Molnupiravir13$7,189
CefuroximeCefuroxime Axetil58$1,055
Labetalol Hcl27$975
Potassium Chloride34$529
Pantoprazole Sodium39$383
Albuterol Sulfate HfaAlbuterol Sulfate16$343
Atorvastatin Calcium36$295
Duloxetine Hcl16$276
Nystatin12$262
Doxazosin Mesylate14$262
Sertraline Hcl18$249
Levocetirizine Dihydrochloride27$215
Venlafaxine Hcl ErVenlafaxine Hcl15$202

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$17$14,07115 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$16$15942 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,717 family providers in Pennsylvania.

Other family in Washington

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →